78% of Doctors Report Delays Due to Prior Auth, Survey Shows

By VirentaNews Staff — May 18, 2026

Despite widespread pledges by insurers and policymakers to reduce administrative barriers in healthcare, the practice of prior authorization continues to delay essential medical treatments for millions of Americans. A growing body of evidence shows that these insurance-mandated approvals are not only persistent but are increasingly contributing to worsened health outcomes and physician burnout. The gap between public commitments to reform and on-the-ground reality reveals a systemic failure to prioritize patient care over cost containment protocols.

Mounting Evidence of Systemic Delays

Recent data from the American Medical Association (AMA) reveals that 94% of physicians report care delays due to prior authorization, with 34% stating such delays have led to serious adverse events, including hospitalization and permanent disability. In a 2023 survey of over 1,000 clinicians, 78% said they spend at least 10 hours per week responding to insurer requests, with 27% spending more than 20 hours—time taken away from direct patient care. Medicare Advantage plans, which now enroll over half of all Medicare beneficiaries, have come under scrutiny: a Reuters investigation found that some insurers deny up to 20% of initial requests, often forcing providers into lengthy appeals. The U.S. Government Accountability Office (GAO) confirmed in a 2022 report that inconsistent criteria, lack of transparency, and slow response times remain widespread, particularly in mental health, oncology, and specialty medications.

Key Players: Insurers, Providers, and Regulators

The primary actors in the prior authorization landscape are private health insurers—including UnitedHealthcare, Anthem, and Humana—alongside federal and state regulators overseeing compliance. While the Centers for Medicare & Medicaid Services (CMS) introduced new rules in 2023 requiring faster decision timelines for Medicare Advantage plans, enforcement remains inconsistent. The AMA and specialty medical societies, such as the American College of Cardiology and American Society of Clinical Oncology, have been vocal critics, advocating for automated pre-approvals and exemption lists for low-risk procedures. Meanwhile, insurers argue that prior authorization is necessary to control costs and prevent unnecessary care, citing internal data that claims the process saves billions annually. However, independent analyses, including a 2021 study published in The American Journal of Managed Care, suggest savings are marginal when factoring in administrative overhead and downstream complications from delayed interventions.

Trade-Offs Between Cost Control and Patient Outcomes

The central trade-off in prior authorization lies between financial stewardship and clinical efficacy. On one hand, insurers maintain that pre-approvals prevent overutilization of expensive imaging, surgeries, and biologics, particularly in chronic conditions like rheumatoid arthritis and multiple sclerosis. On the other, delayed access can lead to disease progression, higher long-term costs, and reduced quality of life. For example, a patient with early-stage cancer may see tumor advancement during a three-week approval wait, shifting treatment from curative surgery to palliative chemotherapy—a far more costly and less effective path. Additionally, the administrative burden disproportionately affects smaller practices lacking dedicated staff to navigate complex insurer portals. While some health systems have adopted prior authorization automation tools, interoperability issues and insurer resistance limit scalability. The net result is a system that may save pennies upfront but risks dollars—and lives—downstream.

Why the Timing of Reform Matters Now

The urgency for overhauling prior authorization has intensified due to converging factors: rising patient volumes post-pandemic, workforce shortages in healthcare, and increased political attention. In 2023, bipartisan legislation known as the Improving Seniors’ Timely Access to Care Act passed the U.S. House unanimously, aiming to standardize and expedite the prior authorization process for Medicare Advantage. Though not yet law, its momentum reflects growing consensus that the status quo is untenable. Simultaneously, digital health infrastructure, including electronic prior authorization (ePA) systems integrated with electronic health records, has matured enough to support real-time decisions in many clinical scenarios. The delay in adopting these tools at scale suggests that inertia and financial incentives—not technical feasibility—are the main barriers to reform.

Where We Go From Here

Over the next 12 months, three scenarios could unfold. In the most optimistic, federal legislation passes and CMS enforces strict timelines and transparency requirements, compelling insurers to adopt automated systems and create exemption lists for high-value, low-variability procedures. A middle path sees incremental progress: some insurers voluntarily streamline processes to improve customer satisfaction and avoid regulatory penalties, while others resist, maintaining patchwork outcomes across states. In the worst-case scenario, legislative efforts stall, provider pushback intensifies, and patients increasingly abandon recommended treatments due to frustration and cost—exacerbating health inequities. Each trajectory hinges on whether financial accountability is balanced with clinical urgency.

Bottom line — despite repeated promises, the healthcare system continues to sacrifice timely patient care at the altar of administrative gatekeeping, and without enforceable reform, prior authorization will remain a barrier, not a safeguard.

Source: The New York Times